TECTB

Across TCGA pan-cancer cohorts, TECTB RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of TECTB’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where TECTB RNA is repressed in tumor relative to normal tissue. In most cancer types TECTB is over-expressed in tumor, although a few such as BRCA and KIRP show the opposite, repressed pattern.

BRCA, KIRP, and THCA are the cancer types where TECTB tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TECTB RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	−0.030	<.001	6	view →
KIRP	Male	All	−0.029	.001	6	view →
THCA	Male	All	−0.279	.003	3	view →
STAD	Female	III,IV	−0.200	.015	2	view →
LIHC	Male	All	+0.234	.025	1	view →
CHOL	Female	All	−0.136	.004	1	view →
READ	All	All	+0.073	.044	1	view →
LUAD	All	All	+0.025	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

TECTB–BRCA

Open the BRCA breakdown →